Ztlido (Lidocaine) Patent Expiration, LOE Window & CMS Spending

Ztlido (Lidocaine) by Scilex: FDA Orange Book LOE 2031-05-10, 8 AB generics, $125.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorScilex
FDA Application & PathwayN207962 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-05-10
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$125.9M
2024 Medicare Part D Spend$50.5M
2024 Medicaid Spend$75.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel